Breaking Finance News

QuintilesIMS (NYSE:Q) target bumped up to $90.00, released a ratings update earlier today by UBS

Yesterday QuintilesIMS (NYSE:Q) traded 1.90% higher at $78.79. The company’s 50-day moving average is $77.50 and its 200-day moving average is $71.10. The last stock close price is up 12.92% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 157,576 shares of the stock were exchanged, down from an average trading volume of 1,104,280

Reporting a possible upside of 0.14%, UBS raised the stock price target of QuintilesIMS (NYSE:Q) to $90.00

See Chart Below

QuintilesIMS (NYSE:Q)

QuintilesIMS has a 52 week low of $55.01 and a 52 week high of $81.26 with a P/E ratio of 24.14 The company’s market cap is currently $0.

In addition to UBS reporting its target price, a total of 15 firms have reported on the stock. The consensus target price is $76.50 with 8 firms rating the stock a strong buy, 9 firms rating the stock a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About QuintilesIMS (NYSE:Q)

Quintiles Transnational Holdings Inc. is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. The Company's segments include Product Development and Integrated Healthcare Services. Its Product Development segment is a contract research organization and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Product Development segment consists of clinical solutions and services, and advisory services. The Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations, and provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.